The contest Valortec ACC1Ó and university evaluation units drive technology to the market.
Baselga is also Physician-in-Chief at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona and Chief of the Division of Oncology/Hematology at Massachusetts General Hospital in Boston.
They have discovered 15 compounds to fight breast and prostate cancer, which in some cases are twice as effective and up to 70% less toxic.
Guttmann is bringing scientist Elkhonon Goldberg to their workshop 'ReModeling the brain', on 25 October in Barcelona.
This international conference will be held on 11 and 12 June in Barcelona, bringing together global experts to outline how the medicine/hospital/patient relationship will evolve in the future.
The Vall d'Hebron Research Institute (VHIR) is one of the main biomedical research centers in Catalonia, located in Barcelona.
Barcelona’s Hospital Clínic and the University Hospital of the Canary Islands have coordinated the first study in the world to compare the two strategies to detect this disease.
Patients with low levels of the MYO1A protein are disease-free less time and have a shorter survival time (less than one year).
This Catalan company won a tender under the Department of Health’s Digitalization of Medical Imaging Plan.
This research, according to Dr. Juan Ángel Recio, could have important implications for cancer “to the point that we could be facing a whole new era in the study of drugs.”
Developed by Drauta